In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

German drug developer InflaRx, which is developing anti-inflammatory therapeutics by targeting the complement system, has ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...

A skin infection has many signs that are often ignored. Here are the ones to watch out for and when to seek medical treatment ...

In a slow news last week a mixed batch of clinical trials results featured. First, US biotech Ultragenyx announced ...